PARIS, France (AFP) — The arthritis drug tocilizumab has shown early promise in preventing extreme inflammation in gravely ill COVID-19 patients, according to a French clinical study. The treatment, which suppresses the body’s natural immune response, was found to reduce “significantly” the number of deaths or life support interventions compared with a control group of patients. The study, carried out by the Paris university hospital trust (AP-HP), looked at 129 people hospitalised with moderate or severe […]





